MedTech innovator award

Johnson & Johnson Quickfire challenge award

DEKRA ISO 13485 Certification

EIC Accelerator € 2.5M grant

FDA Breakthrough Device

Catch us at the 21st ESSKA Congress in Milan.

21st ESSKA Congress

Meet us at the combined 61st NOF Congress & NOV Annual Congress in Rotterdam.

61st NOF Congress & NOV Annual Congress

Meet us at the LSX World Congress in London.

LSX World Congress

Introduction to ATRO Medical

Introduction to ATRO Medical - The Meniscus Company

The US Food & Drug Administration identifies the Trammpolin® meniscus prosthesis as a unique and potentially more effective treatment for knee osteoarthritis patients with a deficient meniscus. At the moment there is no effective treatment available for a large group of these patients.

CEO Jan Hunik is excited to receive the Breakthrough Device Designation: “We still have quite some work to do before we can access the US market and obtain the CE mark for the European market. This designation endorses our conviction that the Trammpolin meniscus prosthesis can make an important impact on the lives of patients suffering from chronic knee pain. We look forward to the more intense collaboration with the FDA and are confident that this will expedite our US timelines.”

The goal of the Breakthrough Device Designation program is to provide patients and their health care providers with timely access to effective medical innovations. The designation ensures a predictable and timely assessment by the FDA. The Trammpolin meniscus prosthesis will have priority in upcoming FDA reviews. The FDA will also give more transparency with respect to the required data for market access of ATRO Medical’s meniscus implant.

Knee Osteoarthritis (KOA) is an irreversibly debilitating disease and is one of the leading causes of disability in Europe and the US. The Trammpolin meniscus prosthesis is a durable anatomically shaped implant that aims to reduce knee pain and restore mobility. Trammpolin is currently being assessed in a first clinical study in the Netherlands. A next study will most likely include clinics in other European countries as well as the United States. ATRO Medical is largely financed by venture capital and is expected to organize a next investment round (Series B) in 2021 to further accelerate its path to the EU and US market.

About ATRO Medical
ATRO Medical is a spin-out from DSM and Radboudumc with offices in Nijmegen and Uden (NL). The company builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials (BMM) that started in 2010 with a consortium of universities, companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has led to the development of the Trammpolin Meniscus Prosthesis and the foundation of ATRO Medical in 2016. More information can be found on www.atromedical.com.

Maarten van der Zanden, Market Development manager
T: +316 3735 3787 E: maarten.vanderzanden@atromedical.com

**Trammpolin® is nowadays known as Artimis®

Dutch medical innovations are rarely granted the Breakthrough Designation by the FDA. Startup ATRO Medical from Nijmegen is the new kid on the block in orthopedics. This week their Trammpolin® meniscus prosthesis (nowadays known as Artimis®), designed to treat chronic knee pain, received the Breakthrough Device Designation from the FDA. The designation demonstrates the innovation potential of this implant and expedites US market access by receiving a priority treatment at the FDA.

Dutch meniscus prosthesis receives FDA Breakthrough Device Designation

Knee osteoarthritis is one of the leading causes of disability worldwide. Loss of meniscus tissue in the younger years can accelerate this disease, leading to complaints such as severe chronic knee pain, stiffness and immobility. Many patients finally end up with a total knee replacement. The Dutch orthopedic startup ATRO Medical has the mission to create a solution for the long, painful period before total knee replacement.

A durable meniscus prosthesis can serve as a new damper in the knee, reducing bone to bone impacts and as such relief pain in the knee joint. An implant for the inner side of the knee joint is currently in clinical research after ten years of development. However, a solution for the outer knee compartment is still missing. Since forty percentage of complaints are apparent in this so- called lateral compartment, many patients would benefit from it.

The consortium of ATRO Medical, the Swiss company Samaplast and the Orthopaedic Research Laboratory (ORL) of the Radboud university medical center receives over € 800,000 EUROSTARS funding as part of a total investment of € 2 million to rapidly change this situation. The team is committed to develop a new meniscus prosthesis for the outer knee compartment and have it ready for a clinical trial within just two years’ time. Both the durable solution for the outer knee compartment and the short development time would be unique in the orthopedic society.

The ORL has been involved in meniscus research for many years as biomechanical expert and was part of the team developing the IP for this innovation. Samaplast is specialized in injection molding of high-precision and medical grade products out of plastic. ATRO Medical is a spin-off from the Radboud university medical center and DSM Biomedical and focuses on the design of durable meniscus prostheses. These three parties together have the required expertise to bring the new meniscus prosthesis to life with EUROSTARS funding.

EUROSTARS supports international innovative projects led by R&D performing SMEs such as ATRO Medical, that help improve the daily lives of people around the world. This EU program aims to bring increased value to the economy, higher growth and more job opportunities.

ATRO Medical is a spin-out from DSM and Radboud University Medical Center with offices in Nijmegen and Uden (NL). The company builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials (BMM) that started in 2010 with a consortium of universities, companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has led to the development of the Trammpolin® Meniscus Prosthesis (nowadays known as Artimis™), and the foundation of ATRO Medical in 2016. More information can be found on www.atromedical.com.

An international consortium led by the Dutch med-tech startup ATRO Medical receives over € 800,000 EUROSTARS funding to address an unmet need for Knee Osteoarthritis patients. These patients often suffer from cartilage degradation related to a dysfunctional meniscus. Based on previous research, the consortium will develop a durable meniscus prosthesis for the outer knee compartment to relief pain and restore mobility. This would change the life of thousands of osteoarthritis patients.

EUROSTARS grants funding for first lateral meniscus prosthesis

What a great recognition for our team of the potential benefit that our meniscus prosthesis may have for Veterans. The incidence of knee osteoarthritis is known to be 10 times higher under military personnel compared to civilians. This is highly correlated to meniscus damage. And almost 20% of those who need surgical meniscus repair will leave the army within 2.5 years.

We would be honored if our Trammpolin® Meniscus Prosthesis could play a part in providing pain relief for these veterans. Besides the recognition, this award comes with grant funding, which will be spent on accelerating the development of the lateral meniscus prosthesis.

The lateral (outside) compartment of the knee joint is known for its’ fast cartilage degradation in a meniscus- deficient knee. It is of utmost importance to provide an early surgical solution for this lateral side since the severity of complaints and disease related health costs increase with ongoing cartilage degradation.

The Dutch startup ATRO Medical is entirely focused on creating a durable solution for patients suffering from the post-meniscectomy pain syndrome. Their meniscus prosthesis under development has already received FDA breakthrough device designation, the EU Seal of Excellence and the MedTech Innovator finalist award by AdvaMed. Their medial prosthesis is currently under investigation in a prospective clinical study in the Netherlands.

1.DOI 10.7205/MILMED-D-15-00589 2.DOI 10.1177/0363546515612076 3.DOI 10.1002/acr.22412

Yess!! ATRO Medical has been named an Awardee in the Veterans Lead QuickFire Challenge organized by Johnson & Johnson Innovation!

ATRO Medical Named Awardee in the Johnson & Johnson Innovation Veterans Lead QuickFire Challenge

10 years ago, the Dutch Arthritis Society has invested in new materials for the research done by Radboud University Medical Center. Which changed the positioning of the health fund together with diverse universities and royal DSM to the upfront of new approach of Polycarbonate Urethan. Which the startup ATRO Medical originated in 2017, located on the Novio Tech campus in Nijmegen, The Netherlands. From there on out the accumulated scientifical knowledge was further developed into an applicable prothesis. 

Jan Hunik, CEO of ATRO Medical: ‘’ Since 2019 the meniscus prosthesis has been used in clinical study with the first patients. The second clinical trial starts in 2021 with a couple of Dutch hospitals. The trials must lead to CE marking of the unique prosthesis especially due to the knowledge provided by Dutch Arthritis Society, which makes this innovation available for European patients.’’

The artificial meniscus prosthesis is meant for patients with knee arthritis. With many of these patients their meniscus was partially removed, or they’re experiencing chronic pain due to knee wear. The meniscus prosthesis offers this group of patients an alternative for the current policies such as pain medication, physiotherapy and the wait to being considered for a total knee replacement. 

Corné Baatenburg de Jong of The Dutch Arthritis Society explains: ‘’It is nice to see that a development throughout the years has eventually been integrated by a team such the one of ATRO Medical and turned it into a new procedure for the patient. They work hard to improve the quality of knee arthritis patients with the use of the meniscus prosthesis. During the implementation, we as organization can support this. We know the way through the path. And thanks to the big patient participation at The Dutch Arthritis Society, we can make sure that their voices are heard. This guarantees that the development fits the patients’ expectations.  

ATRO Medical is a spin-off of DSM & Radboud University Medical Center with offices in Nijmegen & Uden (NL). The startup builds further on knowledge from the public-privates collaboration BioMedical Materials (BMM), started in 2010 as a consortium of universities and companies with financial support of the Dutch government. The collaboration between clinical, biomechanical & polymer-experts which led to development of the Meniscus Prosthesis and establishment of ATRO Medical in 2016. The first clinical study started in 2019. More information can be found on www.atromedical.com

Maarten van der Zanden,  CIO & Market Development manager
T: +316 3735 3787 E: maarten.vanderzanden@atromedical.com

Orthopedic startup ATRO Medical enters a partnership together with the Dutch Arthritis Society for further development of the artificial meniscus. The Dutch startup works on a meniscus prosthesis for people with knee arthritis. The Dutch Arthritis Society supports these developments and shares its experience as patient expert in the field of arthritis. 

The Dutch Arthritis Society supports further development of the meniscus prosthesis of ATRO Medical

The EIC Accelerator program is the most important instrument of the European Commission to support promising healthcare innovations. The program aims to develop and scale up game changing innovations. The EIC Accelerator grant provides access to an investment by the EIC Fund, coordinated by the European Commission and particularly used to bridge the funding gap between market entry and scale up.

The € 2.5 million grant will be spent on accelerating pre-clinical testing of the meniscus prostheses, on health economic analyses and international clinical studies. All efforts combined will fast-track the implementation of this Dutch healthcare innovation. ATRO Medical is the first company worldwide to have solutions for both the inner and outer meniscus close to the clinical stage.

Thousands of patients suffering from chronic knee pain are waiting for these solutions. Their meniscus has been removed as a result of an earlier trauma and they have developed the so-called post-meniscectomy pain syndrome. Orthopedic surgeon and Chief Medical Officer Dr. Tony van Tienen explains, “I see many patients with chronic knee pain in my clinical practice. Most of them are too young for a total knee replacement. However, they should be able to go to work, go shopping or simply walk their dog without constantly being bothered by an aching knee. Our artificial meniscus aims to relieve that pain. Pain free mobility, that is what we strive for.”

ATRO Medical has already received several international recognitions for their thought-leading work like FDA breakthrough device designation, Eurostars funding and the Johnson & Johnson Quickfire award. In the next few years, the company will leverage these endorsements and funds to significantly expand their clinical evidence and achieve market registration. Together with partners like the Dutch Arthritis Society, the Orthopaedic Research Laboratory and international clinics such as the Sint Maartenskliniek, Mayo Clinic and Sporthopaedicum Berlin they are confident to succeed.

The European Commission grants € 2.5 million to ATRO Medical for the accelerated development of their artificial meniscus. The Dutch startup works on the first anatomical meniscus prostheses for patients with chronic knee pain. Their ground-breaking innovation continues to attract international attention, paving the way towards full-scale healthcare implementation.

Meniscus prosthesis receives € 2.5 million EU grant

ATRO Medical’s team constantly commits itself to lessen chronic joint pain. It’s our mission to improve the quality of life of knee patients. Our artificial meniscus is designed to contributed to normal daily life without knee pain.

About us

ATRO Medical is founded with the objective to make a change through cooperation & perseverance. Our innovations contribute to preservation of the knee joint. These new treatment options need to be accessible for both surgeons and patients. Therefore, we’re ahead in contact with insurances before the product is available on the shelf.

Safety: based on elaborate studies and research.

Simplicity: the operations follow surgical intuition. 

Durability: the artificial meniscus offers a solution for a minimum of 5 years. 

Effectiveness: Lessening of pain and improvement of mobility as main objective.

Economical: We’re currently working on a compensation through insurances.

ATRO Medical has a very open character. All employees contribute on their own way to the organizations’ success. Together we have built our most essential values, which are:

Reliability - We’re an organization on which you can build on. We work with integrity, deliver quality and are transparent about our results. 

Innovation - We’re innovative and find ourselves on undiscovered territory. This often offers new insights during unexpected situations which requires a lot of flexibility. 

Collaboration - We’re open to all input that contributes to the success of our meniscus. We’re professional, multidisciplinary and believe in diversity as innovational strength.

What we value as ATRO Medical

Mission & Vision

Creator of the artificial meniscus and our orthopedic knee specialist. 

Tony van Tienen

Our Chief Implementations Officer,  He navigates the route to patients and financial resources.

Maarten van der Zanden

Our Chief Operations Officer, she keeps track on our projects and manages all our operational businesses.

Anita Brinks

He operates our quality management system and oversees or product developments. 

Branco van Minnen

As Clinical Field Director, she is a reliable link towards the clinics as well as the social link in our innovative machine.

José Lugies

Our Senior Scientist, he isn’t afraid to take up a technical challenge and solve the problems related to it

Albert van der Veen

Our Biomechanical Engineer and mastermind in the field of clinical research. He manages that our pre-clinical work and clinical proof strengthen each other.

Thijmen Struik

As communication specialist she brings new marketing & communication insights for our product.

About us

Mission & Vision

The team of ATRO Medical

Tony van Tienen

Maarten van der Zanden

Anita Brinks

Branco van Minnen

José Lugies

Albert van der Veen

Thijmen Struik

Fatima Lamsettef

Our achievements

MedTech innovator award

Johnson & Johnson Quickfire challenge award

DEKRA ISO 13485 Certification

EIC Accelerator € 2.5M grant

FDA Breakthrough Device

Our partners

ATRO Medical B.V.

Contact details

Navigation

Newsletter